Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

Results of the phase II study combining in vivo γδ T-cells stimulator (IPH1101), interleukin 2 and rituximab for patients having follicular lymphoma. The patients were treated with bromohydrin pyrophosphate (BrHPP, Innate Pharma Inc. Marseille, France, at 750 mL/m2, 3 times every 3 weeks), low dose IL-2 (8 MIU, daily for 5 days, every 3 weeks) and rituximab (375 mg/m2, 4 times weekly). There was a dramatic increase of circulating T-lymphocytes without any amplification of other lymphocyte subpopulations including Tregs. a The change of circulating immune cell subpopulations at day 21 as compared to day 0. b Complete response rate (CRR) and objective response rate (ORR) in patients having FL depending on the FLIPI (Follicular Lymphoma International Prognostic Index), i.e., low index and intermediate/poor index. IL2: interleukin 2; Treg: T-regulator; NK: natural killer lymphocytes; C1D8: cycle 1 Day